Washed human platelets were treated with inhibitors of GPx, L-AT and PDI prior to exposure to donors of NO redox derivatives (S-nitrosoglutathione, Angeli's salt and Diethylamine NONOate). Rapid delivery of NO-related signalling into platelets was monitored by cGMP accumulation and DAF-FM fluorescence.
Introduction
S-nitrosothiol compounds (RSNOs), produced by S-nitrosation of cysteine thiols, feature prominently in the biology of nitric oxide (NO) as mediators of both signalling events and nitrosative stress [1] . The easy synthesis, relative stability and NO-related biological activity of RSNOs make them potentially useful therapeutic tools with a wide range of clinical applications [2] , in particular as platelet-selective anti-thrombotic agents [3] . Nevertheless, the NO-related signalling actions of RSNOs are independent of their rate of NO release [4, 5] and the mechanism by which they deliver NO into cells is debated. There exists what has been described as a "gulf between our chemical understanding of S-nitrosothiols and the proposed biological activities of these compounds" [6] . However, a picture is emerging of RSNO action being mediated at the target cell surface via stereoselective recognition sites [7] , L-Amino acid Transporters (L-ATs) [8, 9] and metabolising enzymes [10] [11] [12] .
Several reports have highlighted the possibility that NO delivery may involve an extracellular transnitrosation step in which the RSNO acts as a nitrosonium (NO   +   ) donor, transferring this either to a cell surface thiol-bearing protein such as protein disulphide isomerase (PDI) [13] or to a low molecular weight thiol such as cysteine, prior to trans-membrane transport of S-nitrosocysteine (CSNO) via the L-AT system [9] . A further interesting observation is that extracellular glutathione peroxidase (GPx) potentiates platelet inhibition by RSNOs, possibly by facilitating transnitrosation reactions [14] .
It may be that RSNO action involves a variety of modes of cellular metabolism and transmembrane NO delivery, tailored to provide both signalling specificity and also, under conditions of RSNO excess, cellular defence against nitrosative stress. A further layer of complexity arises from the diverse chemistry of RSNO compounds, which under physiological conditions can give rise to various redox derivatives of NO. Thus metal-catalysed RSNO decomposition produces NO radical (NO˙), transnitrosation involves transfer of nitrosonium cation (NO + ) and S-thiolation reactions release nitroxyl anion (NO -) [15] . There has been recent interest in the fact that these various redox 4 derivatives, in particular nitroxyl, show distinct biological properties [16] , including a differential ability to stimulate generation of the classic second messenger cGMP. In fact, some reports have suggested that NO radical is the only redox form to stimulate soluble guanylate cyclase [17] .
In this study we have investigated the role of GPx, L-AT and PDI in the delivery of NO signalling into human platelets from the RSNO compound S-nitrosoglutathione (GSNO). In addition, we have used well-characterised donors of both NO radical and nitroxyl anion to determine whether L-AT, GPx and PDI mediate intra-platelet delivery of these NO redox derivatives also.
Experimental
In order to establish which, if any, of the candidate enzyme/transporter systems may be involved in the delivery of nitric oxide across the platelet membrane, recognised pharmacological inhibitors of GPx, the L-AT system and PDI were used and NO entry into platelets was measured after addition of NO donors. Three different donors of NO redox derivatives were used: GSNO (an NO + donor), Angeli's salt (an NO -donor), and Diethylamine NONOate sodium salt (DEANO) (a donor of free nitric oxide, NO · ).
Materials and reagents
Angeli's salt was purchased from Merck Biosciences Ltd (Nottingham, UK), 4-amino- 
Preparation of washed platelets
Washed platelets were prepared from informed healthy volunteers who had not received any medication known to alter platelet function for at least 2 weeks before the study.
Blood was anticoagulated with acid citrate dextrose (ACD) and processed within 1 hour of collection. Platelet rich plasma (PRP) was obtained by centrifuging the blood twice at 170g for 10 minutes, keeping the upper layer each time. PRP was acidified with 0.5 M citric acid to pH 6.3 and prostaglandin E 1 (PGE 1 ) (1.5 µM) and apyrase (2 U/ml) were added prior to centrifugation at 1000g for 12 minutes. The platelet pellet obtained was then resuspended in 1.5 ml HEPES buffered saline (HBS), containing NaCl (140 mM), KCl (2.7 mM), Glucose (5 mM), BSA (1 mg ml -1 ) and HEPES (10 mM) (pH 7.3) and loaded onto a Sepharose 2B column (5-6 ml packed Sepharose in a 1.5 cm column equilibrated with HBS). The platelet fraction was eluted with HBS and platelet count adjusted to 200×10 9 l -1 . Finally, CaCl 2 and MgCl 2 were added to a final concentration of 1 mM.
Preparation of S-nitrosoglutathione (GSNO)
GSNO was prepared as previously described [5] by nitrosation under acid conditions.
Briefly, equal volumes of glutathione (20 mM) and sodium nitrite (20 mM) were incubated in the presence of 100 mM HCl on ice for 30 minutes. GSNO was stabilised by addition of 1 mM EDTA. GSNO was freshly prepared each day and stored in the dark on ice until used. The concentration of GSNO was estimated by its absorbance at 334 nm using an extinction coefficient of 0.85 mM -1 cm -1 . 
Preparation of Angeli

Investigation of the role of GPx in NO delivery
Platelet-rich plasma was pre-incubated with 10-1000 µM β-mercaptosuccinic acid or 0.1-10 mM zinc chloride for 30 minutes at 37°C to inhibit GPx, prior to the addition of NO donor. cGMP levels were then measured as described above.
In separate experiments, washed platelet suspensions were supplemented with GPx (Sigma, UK) to final concentrations of 0.1-20 U ml -1 , prior to measurement of cGMP responses. A glutathione peroxidase cellular activity assay kit from Sigma (Poole, UK) was used to measure GPx in platelet poor plasma. Concentrations of 0.0075 U ml -1 were found and this plasma GPx activity was completely inhibited by β-mercaptosuccinic acid and zinc chloride at concentrations of 1000 µM and 10 mM, respectively (data not shown).
Investigation of the role of L-AT in NO delivery
L-leucine, as a typical substrate of the L-AT system, and BCH, as a selective inhibitor of L-AT, were used at concentrations of 1-10 mM to competitively block the activity of this transport mechanism. Both have previously been shown to inhibit the entry of CSNO into human epithelial cells in this concentration range [8] . BCH, L-leucine and, as a control, D-leucine, were pre-incubated with washed platelets for 30 minutes at 37°C prior to the addition of NO donor when measuring cGMP levels, and with DAF-FM-loaded washed platelets when measuring fluorescence as an indicator of NO entry.
Investigation of the role of PDI in NO delivery
The ability of bacitracin, phenylarsine oxide (PAO) and the anti-PDI antibody, RL90 to inhibit the disulphide exchange activity of 0.16 µM PDI (Sigma) was monitored using an insulin turbidity assay, as previously described [18] . cGMP levels and DAF-FM fluorescence were measured after pre-incubation of washed platelets for 30 minutes at 37°C with 0.05-5 mM bacitracin, 1-100 µM PAO and 0.2-20 µg ml -1 RL90.
Results
10 µM GSNO, 10 µM Angeli's salt and 1 µM DEANO were all found to promote a similar cGMP response in washed platelets and these concentrations were therefore used in subsequent studies (figure 1a). When cGMP was measured in PRP, 10-fold higher concentrations of each donor were required.
For studies using DAF-FM fluorescence to monitor delivery of NO x into platelets, 10 µM Angeli's salt and 1 µM DEANO were found to give similar increases in fluorescence intensity (FI) and these concentrations were therefore used in experiments with DAF-FM-loaded platelets. Smaller increases in FI were obtained with GSNO, however treatment of platelets with 100 µM GSNO provided a usable response (figure 1b).
Glutathione Peroxidase
Effect of inhibition of GPx on cGMP generation
cGMP generation stimulated by GSNO, Angeli's salt and DEANO in PRP was inhibited to a minor degree (maximum 30%) by both β-mercaptosuccinic acid and zinc chloride (figure 2), however this inhibition failed to show a clear dose response relationship.
Effect of GPx supplementation on GSNO-stimulated cGMP generation in washed platelets
Addition of GPx had the effect of increasing GSNO-stimulated cGMP production in platelets, however levels of GPx required to show this effect were approximately 1000 times higher than the concentration of GPx found in plasma (0.0075 U ml -1 ). GPx supplementation had no effect on Angeli's salt-or DEANO-stimulated cGMP production ( figure 3 ).
L-Amino Acid Transporter System
Neither BCH (1-10 mM), nor L-leucine (1-10 mM) significantly inhibited cGMP generation stimulated by any of the NO donors (figures 4a and b) . D-leucine was also shown to have no effect (data not shown).
In parallel experiments, NO x entry measured fluorometrically in DAF-FM-loaded platelets was unaffected by either BCH or L-leucine (data not shown).
PDI
Inhibition of PDI by bacitracin, PAO and RL90
All three agents produced concentration-dependent inhibition of PDI activity however the degree of inhibition was smaller with RL90 than with bacitracin or PAO ( figure 5 ). 
Platelet cGMP responses are inhibited by bacitracin
Experiments using YC-1 suggest direct interference of RL90 and PAO with soluble guanylate cyclase
To investigate the inconsistent effects of the different PDI inhibitors on cGMP responses we investigated whether the inhibitors might exert a direct effect on the action of soluble guanylate cyclase, using the NO-independent activator YC-1 [19] . PDI inhibitors were pre-incubated with washed platelets after which 100 µM YC-1 was added. cGMP responses were unchanged with bacitracin (5 mM), increased approximately three-fold with RL90 (20 µg ml -1 ), and almost completely abolished with guanylate cyclase, only experiments using bacitracin to inhibit PDI are regarded as reliable.
NO entry into DAF-FM-loaded platelets is inhibited by bacitracin, RL90 and PAO
Experiments using DAF-FM-loaded platelets indicated that PDI plays a role in delivery of all redox derivatives of NO. Pre-incubation of DAF-FM-loaded platelets with bacitracin, RL90 and PAO produced a dose-dependent inhibition of FI in response to all three NO donor compounds ( figure 7) . Control experiments performed in the absence of NO donors showed that the PDI inhibitors themselves produced no change in DAF-FM fluorescence over the experimental period.
Discussion
The principal finding of this study is that PDI activity is required for the delivery into platelets of NO-related signals from donors of all NO redox derivatives. Under the experimental conditions used, GPx and the L-AT system appeared to be unimportant in NO x delivery.
Two systems, cGMP accumulation and DAF-FM fluorescence, were used to detect the arrival of NO x inside the target platelets and a positive response was obtained with both detection systems following treatment of platelets with donors of all three NO redox derivatives. Previous reports have suggested that only NO˙ is capable of activating soluble guanylate cyclase [17] , however this result was obtained using the purified enzyme and there are numerous data showing that in whole platelets a cGMP response is obtained in response to GSNO [20, 21] , DEANO [5] and Angeli's salt [22] . This indicates either that the responsiveness of soluble guanylate cyclase is in fact wider than previously believed, or that nitroxyl is at least partly converted to NO˙ once inside the cell [23] . Diamino fluorophores, including DAF-FM, are widely used as intracellular indicators of NO˙ production, however is it now recognised that fluorescence marks reaction of the probe with NO x rather than the NO˙ radical itself [24, 25] . Thus in the current study a positive signal is interpreted simply as evidence of NO x entry, and the exact identity of the delivered reactive nitrogen species remains uncertain.
We were interested to investigate the role of GPx in platelet regulation by NO because of its possible clinical significance. In the late 1990s a novel thrombotic tendency was reported, first in a single family [26] and later in a larger study of seven families [27] , in which deficiency of plasma GPx was associated with both platelet resistance to GSNO and an increased incidence of childhood stroke. An earlier paper had suggested that plasma GPx could potentiate the anti-platelet action of GSNO via two mechanisms: a) reduction of lipid peroxides thereby preventing them from inactivating NO, and b) an ability of extracellular GPx to catalyse transnitrosation [14] . Certain observations reported in these studies suggested to us that the second mechanism was more likely.
For example, sodium nitroprusside-induced inhibition of platelet aggregation was not altered by GPx [14] , suggesting its effects might be an RSNO-related phenomenon, and not more generally relevant to other NO donor compounds. Also, intraplatelet GPx (as opposed to extracellular GPx in the plasma) was found to be normal when measured in one affected family [26] , suggesting that the GPx effect was exerted outside the platelet, for example via catalysis of transnitrosation from an RSNO to a target on the exofacial surface of the plasma membrane. Despite these considerations, we did not find evidence in the current study that plasma GPx mediates the transfer of NO-related signalling into platelets. β-mercaptosuccinate and zinc chloride, at concentrations shown to completely inhibit plasma GPx, showed only a limited ability to inhibit cGMP generation following addition of NO donors, and this minor inhibition was not dose-dependent. It should be noted that previous authors monitored platelet aggregation and P-selectin surface expression, whereas we focussed on cGMP accumulation as a marker of intracellular NO delivery. This technical difference may in part explain our different findings.
Consistent with Freedman et al. [14], we found that addition of GPx to washed platelets increased cGMP accumulation in response to GSNO (though not to DEANO or
Angeli's salt), however, the amounts of GPx required were almost 1000-fold higher than the levels we found in plasma. Given this, it appears unlikely that the effect has physiological relevance.
There is ample evidence that CSNO is transported across the plasma membrane in a stereoselective manner via the L-AT system. This has been demonstrated in a variety of cell types including PC 12 neuronal cells [28] , RAW 264.7 macrophages [9] and the carcinoma cell lines A431 and T24 [8] . We found, however, no inhibition of intraplatelet NO x delivery from GSNO, DEANO or Angeli's salt, in the presence of the well characterised inhibitors BCH and L-leucine, at concentrations shown in previous studies to block CSNO uptake on the L-amino acid transporter system [8] . GSNO is not a direct substrate for this transporter, and for L-AT to mediate NO delivery from GSNO extracellular cysteine must be available (either directly or via reduction of cystine) so that CSNO can be produced via transnitrosation, prior to transport [9, 29] . Neither cysteine nor cystine was supplied in our experiments and this may explain why we found no evidence for the involvement of L-AT. The fact remains, however, that all three NO donors were capable of rapidly and effectively bringing about both cGMP accumulation and DAF-FM fluorescence in platelets, and so some other entry mechanism must exist.
The current study produced clear evidence that inhibitors of PDI prevent the intracellular delivery of NO-related signals (cGMP accumulation and DAF-FM fluorescence) from GSNO in a dose dependent manner. These results are consistent with those of Zai et al. [30] and Ramachandran et al. [13] who also found that PDI inhibition produced inhibition of NO delivery from RSNOs (measured as cGMP accumulation and quenching of N-dansylhomocysteine fluorescence, respectively). PDI has been shown to denitrosate GSNO [18] and it is postulated that the NO˙ released by this reaction combines with oxygen in the hydrophobic environment of either the cell membrane or the PDI protein itself to form N 2 O 3 [31], which then passes on the NO signal via nitrosation of intracellular thiols, completing the transmembrane delivery process [13] . We were surprised, however, also to find evidence of PDI involvement in the intracellular delivery of NO x from both DEANO and Angeli's salt. We had anticipated that free NO˙ released by DEANO would be able to diffuse into platelets Recent research has revealed a significant role for both PDI [33] and other thiol isomerases [34, 35] 
